COMP <GO>
CDNA vs UNH // FORWARD P/E MULTIPLE
CareDx Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CDNA 4
— UNH 9
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $87.41 (+22.22%) • MKT CAP: $3.70B
forward-pe
21.0x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDNA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDNA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.20% | 11.47% | -19.67 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 6.48% | -5.81 | UNH | /fcf-yield <GO> |
| Operating Margin | -8.10% | 4.82% | -12.92 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 3.14% | -8.74 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 13.80% | 6.46% | +7.34 | CDNA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.22 | 3.12 | +16.10 | CDNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.9 | 56.0 | +25.85 | CDNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.33 | +0.73 | CDNA | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.0x | 17.1x | +3.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.70B | $364.66B | -$360.96B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDNA REV | UNH REV | CDNA GROSS % | UNH GROSS % | CDNA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $379.8M | $447.57B | 44.0% | 88.7% | $24.9M | $16.07B |
| FY 2024 | $333.8M | $400.28B | 44.0% | 88.3% | $23.0M | $20.70B |
| FY 2023 | $280.3M | $371.62B | 44.0% | 89.6% | -$31.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDNA // BETA 1.06
UNH // BETA 0.33